Transverse Medical
Transverse Medical Inc. is a medical device company dedicated to developing the POINT-GUARD™ Cerebral Embolic Protection device. Their mission is to reduce and eliminate the risk of procedural stroke during cardiovascular procedures by providing maximum cerebral coverage and protection from embolic debris, thereby improving patient outcomes and reducing healthcare costs. Their vision is to ensure that operative and interventional procedures of the heart are without risk of stroke or unnecessary complications.
Industries
Nr. of Employees
small (1-50)
Transverse Medical
Golden, Colorado, United States, North America
Patents
Products
Full‑brain cerebral embolic protection device (catheter‑delivered filter system)
A catheter‑delivered filter system designed to provide maximum coverage of cerebral arch vessels and capture embolic debris during cardiovascular and structural heart procedures to reduce periprocedural stroke risk.
POINT-GUARD™
The POINT-GUARD™ device provides an innovative and dynamic solution to address the unmet need for full brain protection, operator ease of use, and device non-interference. It is set apart as a full brain protection solution and in a class by itself from the single partial protection commercially approved device or other solutions in development.
Full‑brain cerebral embolic protection device (catheter‑delivered filter system)
A catheter‑delivered filter system designed to provide maximum coverage of cerebral arch vessels and capture embolic debris during cardiovascular and structural heart procedures to reduce periprocedural stroke risk.
POINT-GUARD™
The POINT-GUARD™ device provides an innovative and dynamic solution to address the unmet need for full brain protection, operator ease of use, and device non-interference. It is set apart as a full brain protection solution and in a class by itself from the single partial protection commercially approved device or other solutions in development.
Services
Design and conduct of feasibility / first‑in‑human clinical studies for cerebral embolic protection devices in structural heart procedures.
Device concept development, simulation (FEA/CFD), prototyping, and engineering to produce catheter‑based embolic protection systems.
Development and management of regulatory strategies, submission preparation, and quality systems implementation to support device development and approvals.
Design and conduct of feasibility / first‑in‑human clinical studies for cerebral embolic protection devices in structural heart procedures.
Device concept development, simulation (FEA/CFD), prototyping, and engineering to produce catheter‑based embolic protection systems.
Development and management of regulatory strategies, submission preparation, and quality systems implementation to support device development and approvals.
Expertise Areas
- Cerebral embolic protection device development
- Structural heart and TAVR procedural risk mitigation
- Clinical trial management and feasibility study execution
- Medical device regulatory strategy and submissions
Key Technologies
- Filter‑based cerebral embolic protection
- Catheter‑delivered endovascular devices
- Finite Element Analysis (FEA)
- Computational Fluid Dynamics (CFD)
News & Updates
Transverse Medical Inc. announced the completion of its Series B2 capital raise on April 28th, 2025.
Medsider interview with Transverse Medical CEO Eric Goslau discussing leadership, product development, and company growth.
Transverse Medical Inc. announced the completion of its Series B2 capital raise on April 28th, 2025.
Medsider interview with Transverse Medical CEO Eric Goslau discussing leadership, product development, and company growth.